Today: 10 June 2026
Browse Category

NYSE:MRK 19 December 2025 - 29 December 2025

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck shares edged up a penny to $106.79 in Monday afternoon trading, moving in a tight range on volume of about 4.1 million. The Health Care Select Sector SPDR ETF slipped 0.05% as health-care stocks held steady while major indexes fell. Investors are awaiting Fed minutes and monitoring year-end market signals. Merck’s next earnings report is set for February 3.
29 December 2025
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

U.S. stock markets are closed for the weekend as of 2:34 a.m. ET Saturday. Merck last traded near $106.78, up 0.33%. The company is in focus after joining TrumpRx-linked drug pricing deals and announcing 70% discounts on diabetes drugs for U.S. consumers. Trading volume remains thin following a flat Friday session.
27 December 2025
···
Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck shares closed at $106.78 Friday in New York, trading between $106.03 and $107.05 amid thin holiday liquidity. The company was named in a White House deal to cut U.S. drug prices through TrumpRx, offering discounts on drugs including JANUVIA. The S&P 500 ended near 6,929.94, with broader markets muted in post-Christmas trading.
27 December 2025
··
Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

U.S. stock markets were closed Dec. 25 for Christmas and will reopen Dec. 26 after an early close Dec. 24. Merck shares last traded near $106.45. The White House named Merck in new drug-pricing agreements announced Dec. 19, with Merck confirming plans for steep discounts on key diabetes drugs. Merck’s next earnings call is scheduled for Feb. 3, 2026.
26 December 2025
··
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck shares closed at $106.45 on Dec. 24, capping a six-day rally driven by a BMO Capital Markets upgrade to Outperform and a new $130 price target. Analysts cited confidence in Merck’s pipeline as it prepares for Keytruda’s 2028 loss of exclusivity. Recent gains also follow positive oncology data and a European regulatory milestone for Winrevair. U.S. markets were closed Dec. 25 for Christmas.
25 December 2025
·
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck shares hit a 52-week high near $106.50 on December 24 after a six-day, 8.3% rally. The surge followed a BMO Capital Markets upgrade to “Outperform” with a $130 target and positive late-stage trial results for Keytruda combinations in bladder cancer. European regulators advanced WINREVAIR for pulmonary hypertension. U.S. markets were closed December 25.
25 December 2025
··
Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck shares closed near $106.45 on Dec. 24, up 1.3%, hitting a new 52-week high in a shortened Christmas Eve session. The stock contributed to the Dow’s advance as U.S. markets posted record closes. Trading volume remained thin after hours. No new corporate news was released, but investors continued to react to last week’s drug-pricing agreement with the Trump administration.
24 December 2025
··
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck shares hit a 12-month high near $106 on December 24, 2025, capping a 30% rally over three months. The surge follows a Trump administration deal requiring Merck to cut prices on drugs like Januvia for Medicaid and direct-to-consumer sales. Analysts cite optimism about Merck’s growth beyond Keytruda’s patent expiration and progress on new drugs.
24 December 2025
··
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck closed Tuesday at $105.04, up 0.3%, then slipped to about $104.81 in after-hours trading. The stock is trading near its 52-week high of $105.84 after gains tied to new White House drug-pricing agreements and FDA fast-track headlines. Merck will sell several diabetes drugs at roughly 70% off list prices under the TrumpRx plan.
24 December 2025
··
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck shares traded near $104.68 midday Tuesday, little changed after the company joined TrumpRx drug-pricing agreements offering tariff relief in exchange for lower prices on Medicaid and some cash-pay drugs. Merck will provide Januvia and Janumet at about 70% off list price to eligible U.S. patients. Investors are weighing policy clarity and late-stage pipeline prospects as Keytruda nears loss of exclusivity.
23 December 2025
··
Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Merck announced a new U.S. drug-pricing agreement, pledging to offer Januvia and related diabetes drugs at about 70% off list prices through a direct-to-patient program. The company also reached a deal with the Commerce Department to delay Section 232 tariffs for three years. Merck shares closed at $101.09, near the top of their 52-week range. The next earnings report is expected in early February 2026.
22 December 2025
·
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck shares closed at $101.09 Friday, up 0.4%, then dipped slightly after hours as investors reacted to new U.S. drug-pricing agreements and FDA acceleration for two pipeline drugs. Trading volume surged to 43.6 million shares after the Trump administration and major pharma firms, including Merck, finalized deals to cut drug prices and grant tariff relief.
20 December 2025
··
1 … 3 4 5 6 7 8

Stock Market Today

  • Starbucks Considers Selling Stake or IPO for Japan Unit Valued at $3.1 Billion
    June 10, 2026, 11:25 AM EDT. Starbucks is exploring strategic options for its Japan unit, including a potential sale of a stake or an initial public offering (IPO). The coffee chain has engaged in preliminary discussions with investment banks regarding these possibilities. The Japan unit could be valued at as much as $3.1 billion, reflecting its significant market presence in the region. This move aligns with Starbucks' broader strategy to optimize its global operations and capitalize on strong demand in Asia.

Latest articles

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

10 June 2026
Dow drops 0.55% to 50,592 after May CPI jumps 4.2% year-on-year, matching forecasts but fueled by a 7% surge in gasoline prices and rising energy costs, as renewed U.S.-Iran tensions and sharp losses in AI and industrial stocks add to investor caution, with Super Micro Computer plunging 14.2% on $7 billion equity plans and XPO, J.B. Hunt, Old Dominion falling up to 6.2% after Amazon expands freight service.
S&P 500 Swings After Hot CPI, AI Names Under Pressure

S&P 500 Swings After Hot CPI, AI Names Under Pressure

10 June 2026
May inflation jumped 4.2%—the fastest pace since April 2023—matching forecasts but keeping the Fed on hold, as energy prices fueled the rise; S&P 500 and Nasdaq steadied after early losses, but AI-linked stocks slid, with Super Micro Computer tumbling on a $7 billion share sale plan that risks diluting investors.
Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Go toTop